 "Lupin receives approval from USFDA for generic Apixaban tablets")
Drug firm Lupin Monday said it has received a tentative nod from the US health regulator to market its generic Apixaban tablets.
The company has received the tentative approval from the United States Food and Drug Administration (USFDA) to market Apixaban tablets in the strengths of 2.5 mg and 5 mg, Lupin said in a filing to BSE.
The product is a generic version of Bristol-Myers Squibb Company's Eliquis tablets in the same strengths, it added.
Eliquis tablets 2.5 mg and 5 mg had annual sales of approximately $6,366 million in the US, Lupin added.
The tablets are used for reducing the risk of stroke and systemic embolism in non valvular atrial fibrillation, among other purposes.
Shares of Lupin Monday closed at Rs 815.05 per scrip on BSE, down 2.96 per cent from the previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app